BJ ENERGY INTL (00686) intends to subscribe for approximately 6.6% equity interest in the listed Australian company Highfield Resources.
Beijing Energy International (00686) announced that on September 23, 2024, the company and the target company Highfi...
BJ ENERGY INTL (00686) announced that it has entered into a share subscription agreement with the target company Highfield Resources Limited on September 23, 2024. The company intends to subscribe for approximately 6.6% of the target company's issued share capital after the issuance of subscription shares. The subscription price for each share is 0.5 Australian dollars.
Highfield Resources Limited is a limited liability company registered in Australia, with its shares listed on the Australian Stock Exchange (ASX code: HFR). The target company is primarily engaged in mineral exploration and potassium fertilizer mining in Spain, including advancing its core project, the Muga project.
The board believes that the subscription is in line with the group's investment strategy. It will further enhance the group's presence in Spain and in the fields of mining, high-end chemicals, power, new energy materials, and high-end equipment manufacturing. The group sees the subscription as a unique opportunity to expand its business into attractive sectors and achieve synergies with its existing operations.
Related Articles

ZYLOXTB(02190) spent 1.2531 million Hong Kong dollars to repurchase 50,000 shares on September 16th.

CN CULTURAL T&A(00542): The sales process for the flagship project Germany City is expected to be completed by the end of 2025.

Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical research on the combined use of SHR-1826 with other drugs for injection has been approved.
ZYLOXTB(02190) spent 1.2531 million Hong Kong dollars to repurchase 50,000 shares on September 16th.

CN CULTURAL T&A(00542): The sales process for the flagship project Germany City is expected to be completed by the end of 2025.

Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical research on the combined use of SHR-1826 with other drugs for injection has been approved.
